Cargando…

Inhibition of prostate cancer cell growth in vivo with short hairpin RNA targeting SATB1

Despite previous advances, the treatment options for prostate cancer remain limited. For the purposes of gene knockdown, the utility of RNA interference has been demonstrated and is considered to have therapeutic potential. In the present study, a short hairpin RNA (shRNA) was used to assess the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiang, Hu, Shi-Cheng, Yang, Chun-Sheng, Chen, Jia-Cun, Zheng, Jun-Nian, Sun, Xiao-Qing, Wang, Jun-Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678242/
https://www.ncbi.nlm.nih.gov/pubmed/29151908
http://dx.doi.org/10.3892/ol.2017.7006
Descripción
Sumario:Despite previous advances, the treatment options for prostate cancer remain limited. For the purposes of gene knockdown, the utility of RNA interference has been demonstrated and is considered to have therapeutic potential. In the present study, a short hairpin RNA (shRNA) was used to assess the effect of special AT-rich sequence binding protein (SATB1) downregulation on the growth and metastatic potential of prostate cancer in xenograft nude mice. A plasmid carrying shRNA targeting SATB1, pSilencer-SATB1-shRNA, was successfully engineered. Using this plasmid, significant downregulation of SATB1 mRNA and protein expression in the DU145 prostate cancer cells was observed. pSilencer-SATB1-shRNA was demonstrated to be markedly efficacious against prostate cancer xenografts in nude mice. These results may lead to a novel method of improving gene therapy efficacy against prostate cancer via regulating the function of SATB1.